Evidence map›Paper›PMID 19148292›Full record

ArticlePloS one2009

Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection.

Jun Hayakawa, Kareem Washington, Naoya Uchida, Oswald Phang, Elizabeth M Kang, Matthew M Hsieh, John F Tisdale

Abstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Development and clinical translation ofComputational and structural biotechnology journal · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Novel cell and gene therapies for HIV.Cold Spring Harbor perspectives in medicine · 2012
    Review
  10. High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2012
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun HayakawaNational Institutes of Diabetes and Digestive and Kidney Disorders (NIDDK) and National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Kareem Washington
Naoya Uchida
Oswald Phang
Elizabeth M Kang
Matthew M Hsieh
John F Tisdale

Funding

Preclinical and Clinical Studies in Gene Therapy for Sickle Cell DiseaseZIAHL006008 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI TISDALE, JOHN · 2009 to 2025
$14.6M
Gene Therapy Clinical Trials for Chronic Granulomatous DiseaseZIAAI000991 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANG, ELIZABETH · 2009 to 2019
$3.4M
Gene Therapy Clinical Trials for Chronic Granulomatous DiseaseZ01AI000991 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI KANG, ELIZABETH · 2007 to 2008
$388k
Intramural NIH HHS
6 · The paper itself

Abstract

We previously reported the efficacy of nonmyeloablative allogeneic transplantation in 2 HIV positive recipients, one of whom received retrovirus transduced hematopoietic stem cells to confer resistance to HIV. Here we report an assessment of retroviral integration sites (RISs) recovered out to 3 years post-transplantation. We identified 213 unique RISs from the patient's peripheral blood samples by linear amplification-mediated PCR (LAM-PCR). While vector integration patterns were similar to that previously reported, only 3.76% of RISs were common among early (up to 3 months) and late samples (beyond 1 year). Additionally, common integration sites were enriched among late samples (14.9% vs. 36.8%, respectively). Three RISs were found near or within known oncogenes, but 2 were limited to early timepoints. Interestingly, an integration site near the MDS1 gene was detected in long-term follow-up samples; however, the overall contribution of MDS1 integrated clone remained stably low during follow-up.

Indexed as

Gene TargetingVirus IntegrationDNA-Binding ProteinsGenetic TherapyGenetic VectorsHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHIV InfectionsHumansMDS1 and EVI1 Complex Locus ProteinNeoplasm ProteinsProto-OncogenesRetroviridaeTranscription FactorsTransduction, GeneticDNA-Binding ProteinsMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanNeoplasm ProteinsTranscription Factors

Identifiers

PMID19148292
PMCPMC2615408

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.